MPM BioImpact’s Repare Therapeutics RPTX Stock Holding History

MPM BioImpact’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-819,924	Closed	-$1.44M	–	48
2025 Q3	$1.44M	Hold	819,924	–	–	0.24%	39
2025 Q2	$1.14M	Hold	819,924	–	–	0.2%	42
2025 Q1	$808K	Sell	819,924 -411,230	-33%	-$496K	0.14%	42
2024 Q4	$1.61M	Sell	1,231,154 -408,695	-25%	-$1.22M	0.23%	47
2024 Q3	$5.64M	Hold	1,639,849	–	–	0.85%	31
2024 Q2	$5.41M	Hold	1,639,849	–	–	0.84%	37
2024 Q1	$7.72M	Hold	1,639,849	–	–	1.24%	33
2023 Q4	$12M	Hold	1,639,849	–	–	2.8%	12
2023 Q3	$19.8M	Hold	1,639,849	–	–	5.29%	4
2023 Q2	$17.3M	Hold	1,639,849	–	–	3.49%	9
2023 Q1	$16.1M	Hold	1,639,849	–	–	4.19%	10
2022 Q4	$24.1M	Hold	1,639,849	–	–	6.26%	4
2022 Q3	$19.9M	Hold	1,639,849	–	–	4.71%	6
2022 Q2	$22.9M	Hold	1,639,849	–	–	6.37%	3
2022 Q1	$23.4M	Hold	1,639,849	–	–	6.27%	4
2021 Q4	$34.6M	Hold	1,639,849	–	–	6.3%	3
2021 Q3	$43M	Sell	1,639,849 -36,238	-2%	-$1.17M	6.67%	3
2021 Q2	$52.3M	Sell	1,676,087 -393,662	-19%	-$12.9M	8.59%	4
2021 Q1	$63.5M	Sell	2,069,749 -318,588	-13%	-$10.8M	7.98%	5
2020 Q4	$81.9M	Hold	2,388,337	–	–	14.39%	2
2020 Q3	$73.5M	Hold	2,388,337	–	–	17.71%	1
2020 Q2	$74.1M	Buy	+2,388,337	New	+$76.7M	19.7%	1

Other funds holding RPTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MPM BioImpact's RPTX Position: Q4 2025 in Review

MPM BioImpact sold out of Repare Therapeutics (RPTX) in Q4 2025, closing a stake of 819,924 shares — an estimated $1.44M sold.

MPM BioImpact first reported a position in RPTX in Q2 2020 and held it in 22 quarters. The position peaked at $81.9M in Q4 2020. 46 funds tracked by Wall St. Rank hold RPTX as of Q4 2025.

MPM BioImpact reported no remaining Repare Therapeutics position as of Q4 2025 after selling out during the quarter.
MPM BioImpact sold 819,924 Repare Therapeutics shares in Q4 2025, an estimated $1.44M.
MPM BioImpact first reported a position in Repare Therapeutics in Q2 2020 and held it in 22 quarters.
MPM BioImpact's Repare Therapeutics position peaked at $81.9M in Q4 2020.
46 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.